Phase 1 ARC101 CLDN6-directed T-cell receptor engager trial in advanced cancers.

A first-in-human trial assessing escalating doses and expansion cohorts of ARC101 as monotherapy in patients with advanced or metastatic solid tumors, including testicular and ovarian cancers expressing CLDN6. This study, sponsored by Third Arc Bio, will evaluate safety, tolerability, pharmacokinetics, and antitumor activity over a 21-day toxicity assessment period.